drugset / Trial / NCT01892709

Titration of Intravenous Hydromorphone

NCT01892709

Phase 4 Completed 215 enrolled Montefiore Medical Center
NaSingle-groupOpen-labelTreatment

Summary

This is an exploratory, hypothesis-generating safety and efficacy study for patients who come to the ER in acute (less than 7 days in duration) severe pain. Patients with chronic pain will not be enrolled. Eligible patients will receive up to a maximum of 4 mg IV hydromorphone over a 4 hour period. Hydromorphone will be given as 1 mg increments based on how the patient responds to the question, "Do you want more pain medicine?". This question will be asked repeatedly 30 minutes after the patient answers "no" or 30 minutes after the most recent dose of IV hydromorphone (which occurs if the patient answers "yes"). Up to 10% (approximately 30 patients) will serve as a pilot at the start of the study.

Timeline

Start
2013-06
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydromorphone Other / unclassified 1 mg Intravenous

Indications

No indication recorded.